about
Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approachesSmall Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases.The Association between genetic variations of CHI3L1, levels of the encoded glycoprotein YKL-40 and the lipid profile in a Danish populationAlcohol-induced Hyperlipidemia Is Ameliorated by Orally Administered DWP208, a Sodium Succinate Form of ZYM201Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatmentNiacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapyThe Association Between the Uncoupling Protein-1 Gene A-3826G Polymorphism and High-density Lipoprotein Cholesterol in A General Japanese Population: A Consideration of the Obesity Status.Usefulness of the triglyceride-high-density lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort)Atherogenic dyslipidemia.Diabetes and increased lipid peroxidation are associated with systemic inflammation even in well-controlled patients.Atherosclerosis prevention and treatment in children and adolescents.Obesity-related cardiorenal disease: the benefits of bariatric surgery.Increased leisure-time physical activity is associated with lower prevalence of the metabolic syndrome in 64-year old women with impaired glucose tolerance.High-density lipoprotein cholesterol affects early endothelial progenitor cell number and endothelial function in obese women.Hypocholesterolemic and Anticarcinogenic Effect of Vicia faba Protein Hydrolyzates.
P2860
Q26866207-75B7F66A-C2ED-45FE-9EAE-C2FE6FFAFAE9Q33717612-A9C6963D-52F5-4FEE-A02E-E203C75AAC50Q34447892-0B7BF447-E555-42E4-8AF4-611F3E943270Q34974185-64600EE3-5B04-4114-B66D-AF09018C6BE8Q35029623-E83BE0F5-8BBF-456A-8AD7-1A4D3CFA372FQ35739667-DD8B0E56-FBFD-44CF-9EB0-05F624648030Q35756939-930B8169-5EA6-40AF-99C3-F1D4425067DFQ37122213-9773BDFB-9647-45F2-A680-CBED269D843BQ37413996-21F003F2-E896-4E26-BBFF-0E8BFF118A0DQ37431527-92A5468A-AB9F-4BC9-AA46-686EDD9FDC54Q37732240-9F635BCD-3578-4D22-A9CB-D5D4018A3612Q38126800-8F3BCA11-9180-40B7-8F1A-D14AA60795D6Q43800378-FE084214-C2B2-46AE-BBCE-5C51B587D72EQ51260780-4266B8C0-993C-4502-8317-CBB0982CEBB3Q51711036-27548A81-DE8A-4BEB-85F0-B957A1E7C626
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
The metabolic basis of atherogenic dyslipidemia.
@ast
The metabolic basis of atherogenic dyslipidemia.
@en
type
label
The metabolic basis of atherogenic dyslipidemia.
@ast
The metabolic basis of atherogenic dyslipidemia.
@en
prefLabel
The metabolic basis of atherogenic dyslipidemia.
@ast
The metabolic basis of atherogenic dyslipidemia.
@en
P1433
P1476
The metabolic basis of atherogenic dyslipidemia.
@en
P2093
Aaron I Vinik
P356
10.1016/S1098-3597(05)80065-1
P577
2005-01-01T00:00:00Z